Anticoagulant News and Research

RSS

Researchers reveal molecular structure of blood-clotting enzyme

Using state-of-the-art robotic and x-ray crystallographic equipment, researchers at Saint Louis University have revealed for the first time the molecular structure of the zymogen, or inactive, form of a blood-clotting enzyme.

3 Nov 2010

Boehringer Ingelheim announces availability of PRADAXA in U.S. pharmacies

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that its new oral anticoagulant, Pradaxa® (dabigatran etexilate mesylate) 150mg capsules, will be available starting Wednesday by prescription in pharmacies across the United States, including CVS/pharmacy, Rite Aid, Walmart, Target, Kmart® and The Kroger Co. In addition, leading independents under the Health Mart®, Good Neighbor Pharmacy® and Medicine Shoppe® banners will be stocked.

2 Nov 2010

Clear guidelines needed for consistent diagnosis and treatment of childhood stroke

Researchers are calling for clear guidelines on childhood stroke after a study, published in the November issue of Acta Paediatrica, found wide variations in time lag to diagnosis, investigation and treatment.

1 Nov 2010

Health Canada approves PRADAX for preventing stroke in AF patients

Health Canada, the Canadian health authority, has approved PRADAX™ (dabigatran etexilate), Boehringer Ingelheim's novel, oral direct thrombin inhibitor for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF) in whom anticoagulation is appropriate, marking the second approval of this new oral anticoagulant following the recent marketing authorisation by the US Food and Drug Administration (FDA).

30 Oct 2010

Experts at XXXIII World Congress present new clinical challenges about thrombotic disorders

Pharmaceutical Strategic Initiatives announced today that some of the leading experts in the field of thrombosis and anticoagulation provided their perspective and assessment of new clinical challenges at a recent symposium held at the XXXIII World Congress of the International Society of Hematology held in Jerusalem, Israel on October 12, 2010.

30 Oct 2010

Venous Disease Coalition launches new VTE Toolkit for health professionals

The Vascular Disease Foundation's Venous Disease Coalition announced the launch of its new VTE Toolkit, A Practical Overview for Health Professionals. This toolkit was developed by the Venous Disease Coalition (VDC).

28 Oct 2010

Health Canada approves PRADAX anticoagulant for stroke prevention in AF patients

Boehringer Ingelheim Ltd. today announces that Health Canada has granted approval of PRADAX (dabigatran etexilate), an oral anticoagulant for the prevention of stroke and systemic embolism in adults with atrial fibrillation in whom anticoagulation is appropriate. PRADAX is the first innovative drug approved in Canada in more than two decades to reduce the risk of stroke in Canadians with atrial fibrillation.

28 Oct 2010

Aspirin reduces risk of death from prostate cancer

Men with prostate cancer who take anticoagulants like aspirin in addition to radiation therapy or surgery may be able to cut their risk of dying of the disease by more than half, according to a large study presented on November 3, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego. The study involved more than 5,000 men with localized cancer whose disease had not spread beyond the prostate gland.

26 Oct 2010

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).

21 Oct 2010

FDA approves Boehringer Ingelheim's Pradaxa for stroke risk reduction in patients with non-valvular AF

The US Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate), Boehringer Ingelheim's novel, oral direct thrombin inhibitor for stroke risk reduction in patients with non-valvular atrial fibrillation (AF) marking the first approval of a new oral anticoagulant in the U.S. in more than 50 years.

20 Oct 2010

Pradaxa capsules receive FDA approval for reducing stroke and systemic embolism risk in AFib patients

The U.S. Food and Drug Administration (FDA) has approved Pradaxa (dabigatran etexilate) capsules to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AFib).

20 Oct 2010

Anticoagulant Pradaxa receives FDA approval for prevention of stroke in atrial fibrillation patients

The U.S. Food and Drug Administration today approved Pradaxa capsules (dabigatran etexilate) for the prevention of stroke and blood clots in patients with abnormal heart rhythm (atrial fibrillation).

20 Oct 2010

Stony Brook professor receives NIH grant to optimize cardiovascular devices

Danny Bluestein, Ph.D., Professor of Biomedical Engineering at Stony Brook University, has been awarded a five-year, $7.5 million grant by the National Institutes of Health. The award marks the first time a Stony Brook professor has received a Phase II Quantum Grant, given by The National Institute of Biomedical Imaging and Bioengineering (NIBIB), a division of the NIH, to make a profound improvement or quantum leap forward—in health care.

14 Oct 2010

Way of VAD implantation can impact stroke occurrence

A surgical team from the University of Central Florida College of Medicine and Arnold Palmer Hospital for Children, Orlando, has presented findings from the first study to demonstrate that the way a ventricular assist device (VAD) is implanted can have an impact on whether or not a patient may have a stroke while the device is in use.

6 Oct 2010

Research Roundups: Racial Disparities at end of life; stopping medicine mistakes; Grand Junction, Colorado's Cost Lessons

Racial Disparities In The Outcomes Of Communication On Medical Care Received Near Death Black patients receive more life prolonging measures and less comfort-directed care at the end of life (EOL) than white patients, such as increased rates of resuscitation, intensive care unit hospitalization, and feeding tube use at the EOL, write the authors of this study that examined whether differences in patient-physician communication contribute to these differences.

4 Oct 2010

New genetic screening program to reduce risk associated with Plavix

Beginning this month, all patients undergoing cardiac catheterization at Vanderbilt University Medical Center will be tested for a genetic variation that can affect their response to Plavix, the most commonly prescribed clot-preventing drug for heart patients and one of the most commonly prescribed drugs worldwide.

29 Sep 2010

Venous thromboembolism drugs to experience robust growth by 2019

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven primarily by the launch and widespread uptake of novel oral anticoagulants, the combined markets for drugs used in the treatment and prophylaxis of venous thromboembolism will experience robust growth, increasing from $2.9 billion in 2009 to more than $5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

28 Sep 2010

CSDH disease causes high mortality rate in elderly population

An in-depth scientific article published in the Journal of Neurosurgery reveals that a fairly common disease in the elderly has a high mortality rate long after patients have undergone what is considered routine treatment. Chronic subdural hematoma in the elderly: not a benign disease reviews the cases of 209 patients with chronic subdural hematoma (CSDH).

27 Sep 2010

New analytical technique to improve personalized medicine

In the future, even before the start of the treatment, physicians will be able to establish how patient's blood binds a given medicine and what doze should be applied in order to obtain the concentration in the body that would be optimal for the treatment. A new simple method of analysis of chemical reactions proceeding in solutions has been developed in the Institute of Physical Chemistry of the Polish Academy of Sciences.

23 Sep 2010

FDA Advisory Committee recommends approval of dabigatran etexilate for stroke prevention in AFib patients

The U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee today voted 9 to 0 in favor of approving dabigatran etexilate for stroke prevention in patients with atrial fibrillation (AFib). An estimated 2.3 million Americans have AFib and the prevalence is expected to increase 2.5 fold to 5.6 million by 2050, reflecting the growing population of elderly individuals.

21 Sep 2010

Anticoagulant News and Research

Researchers reveal molecular structure of blood-clotting enzyme

Boehringer Ingelheim announces availability of PRADAXA in U.S. pharmacies

Clear guidelines needed for consistent diagnosis and treatment of childhood stroke

Health Canada approves PRADAX for preventing stroke in AF patients

Experts at XXXIII World Congress present new clinical challenges about thrombotic disorders

Venous Disease Coalition launches new VTE Toolkit for health professionals

Health Canada approves PRADAX anticoagulant for stroke prevention in AF patients

Aspirin reduces risk of death from prostate cancer

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

FDA approves Boehringer Ingelheim's Pradaxa for stroke risk reduction in patients with non-valvular AF

Pradaxa capsules receive FDA approval for reducing stroke and systemic embolism risk in AFib patients

Anticoagulant Pradaxa receives FDA approval for prevention of stroke in atrial fibrillation patients

Stony Brook professor receives NIH grant to optimize cardiovascular devices

Way of VAD implantation can impact stroke occurrence

Research Roundups: Racial Disparities at end of life; stopping medicine mistakes; Grand Junction, Colorado's Cost Lessons

New genetic screening program to reduce risk associated with Plavix

Venous thromboembolism drugs to experience robust growth by 2019

CSDH disease causes high mortality rate in elderly population

New analytical technique to improve personalized medicine

FDA Advisory Committee recommends approval of dabigatran etexilate for stroke prevention in AFib patients

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News